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Abstract
Background: Mouse AA-amyloidosis is a transmissible disease by a prion-like mechanism where amyloid fibrils act by
seeding. Synthetic peptides with no amyloid relationship can assemble into amyloid-like fibrils and these may have seeding
capacity for amyloid proteins.
Principal Findings: Several synthetic peptides, designed for nanotechnology, have been examined for their ability to
produce fibrils with Congo red affinity and concomitant green birefringence, affinity for thioflavin S and to accelerate AA-
amyloidosis in mice. It is shown that some amphiphilic fibril-forming peptides not only produced Congo red birefringence
and showed affinity for thioflavin S, but they also shortened the lag phase for systemic AA-amyloidosis in mice when they
were given intravenously at the time of inflammatory induction with silver nitride. Peptides, not forming amyloid-like fibrils,
did not have such properties.
Conclusions: These observations should caution researchers and those who work with synthetic peptides and their
derivatives to be aware of the potential health concerns.
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Introduction
The amyloidoses comprise a large group of diseases in which
abnormally folded proteins self-assemble into beta pleated sheet
fibrils and form mainly extracellular deposits. More than 25
different human proteins are known as main amyloid fibril
proteins [1]. In each disease there is only one specific amyloid fibril
protein. In one of the disorders, secondary or reactive amyloidosis,
a protein named AA is deposited as fibrils in most tissues, leading
to a life-threatening condition mainly by deposits in the kidneys.
Protein AA is derived from a plasma precursor, serum AA (SAA)
by removal of a C-terminal part of the protein [2]. Plasma SAA is
an acute phase reactant, synthesized by the liver as response to
interleukin (IL) -1, IL-6 and tumor necrosis factor a. At an acute
inflammation, the plasma concentration of SAA can increase as
much as 1,000 times and reach as high as 1 mg/ml (1 g/liter) [3].
AA-amyloidosis is a consequence of a chronic inflammatory
disease with persistently high plasma concentration of SAA.
Infectious diseases like tuberculosis and leprosy are known causes
of AA-amyloidosis although rheumatic diseases, particularly
rheumatoid arthritis, are more commonly found to be complicated
by AA-amyloidosis in the western world [4]. Only a fraction of
patients with those conditions does, however, develop AA-
amyloidosis. The reason for this is unknown.
SAA is a conserved protein and AA-amyloidosis is commonly
found in many mammalian and avian species, including mouse
(Mus musculus). Like human, mouse acute phase SAA is a product
of two closely related genes resulting in SAA1 and SAA2. In the
mouse, only SAA 1 is amyloidogenic [5]. Murine AA-amyloidosis
can occur spontaneously but can also be induced by an
inflammatory challenge. Typically, such amyloidosis appears after
several weeks of persistent inflammation. This long indolent phase
can be shortened drastically by administration of a small amount
of an extract of amyloid from an already amyloidotic mouse [6,7].
The nature of the active principle in the extract, called ‘amyloid
enhancing factor’ (AEF) has been a matter of long discussions but
recent studies indicate that it is the amyloid fibril itself acting as a
seeding agent for amyloid fibril elongation [8]. In addition, the
murine systemic apolipoprotein A-II-derived amyloidosis exhibits
a similar mechanism of transmissibility [9].
Formation of amyloid-like fibrils can easily be mimicked in vitro
with many natural or synthetic peptides which may spontaneously
assemble into beta sheet fibrils with typical amyloid properties,
including affinity for the dye Congo red and green birefringence
after such staining [10–13]. Typically, this occurs after a lag period
under which fibrils are not detectable [14]. Seeding a peptide
solution with a small amount of preformed fibrils of the same kind
dramatically reduces the lag period [15]. Already small differences
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in amino acid sequence can greatly reduce nucleation efficacy
[16] but cross-nucleation may occur with amyloid-like fibrils of
a biochemical composition different from that in the solution
[17].
We have shown earlier that synthetic amyloid-like fibrils from
some short peptides corresponding to segments of amyloid fibril
proteins may have AEF-activity in the experimental AA-amyloid
mouse system [18,19]. Such fibrils, when given intravenously
at the induction of AA-amyloidosis with silver nitrate, reduced
the lag phase before AA-amyloidosis developed. Although the
exact mechanism by which the synthetic fibrils worked is
unknown, it was shown that the first AA-amyloid developed
exactly where the synthetic fibrils could be traced in tissues. It is
therefore likely that the fibrils acted as direct seed on which AA-
fibrils developed. Although amyloid always is a pathological
deposition in human, there are amyloid-like fibrils occurring
normally in nature such as silk and bacterial curli. Also such fibrils
can exert AEF-effect [20].
Self-assembling peptides constitute a potentially very valuable
tool for biomaterials, which can be used for different purposes, e.g.
as scaffolds for tissue repair [21]. Different strategies are used and
one is to construct peptides which assemble into stable b-sheet
structures that, under certain circumstances can form fibrils and,
consequently, may be amyloid-like. In the present study we have
investigated the amyloidogenic properties of a group of designed
synthetic peptides. The peptides were further studied for their
ability to enhance AA-amyloidosis in mice.
Materials and Methods
Synthetic peptides
Peptides used in this study were commercially synthesized
(Synpep, Dublin, CA) and a kind gift from Dr. Shuguang Zhang,
MIT, Cambridge, MA. The purity of the peptides was evaluated
by reversed phase high performance liquid chromatography and
the expected masses were confirmed with mass spectroscopy.The
peptides and their intended structures are shown in Table 1.
Fibril formation
The ability of the peptides to form amyloid-like fibrils was
tested with a standard method [22]. Peptides were dissolved at
a concentration of 20 mmol/l in dimethylsulfoxid (DMSO)
(stock solution). Aliquots were diluted 1:10 with distilled water
to 2 mmol/l and incubated at room temperature without shaking.
Small aliquots (0.8 ml) were removed at different time points
(5 min, 24 hours, 1 week, 2 weeks, 1 month, 3 months, 1 year),
placed on glass slides, air dried and stained with alkaline Congo
red for examination in polarized light [23]. The one-year-old
material was tested for binding of thioflavin S. Dried droplets
were stained as described [24], mounted in water-based mounting
media and investigated in a fluorescence microscope (exitation
440 nm and emission 488 nm). After one month, small aliquots
were also taken for electron microscopy. These were diluted
further 1:10 in distilled water, applied on formvar-coated copper
grids, dried and contrasted with 1% sodium phosphotungstate
and viewed in a Jeol 1200 electron microscope operated at
80 kV.
Peptide No. 12 was also available as preformed 1% hydrogel
(PuraMatrix, BD Biosciences, San Jose, CA) and had been
dissolved directly in water.
Amyloid induction
Outbreed female NMRI mice were obtained from B & K
Universal, So¨derta¨lje, Sweden. After an inflammatory challenge
with silver nitrate subcutaneously, this strain of mice develops AA-
amyloidosis after .5 weeks [8]. The mice were 6–8 weeks old at
the beginning of the experiments and had free access to water and
pellets (type R 36; Lactamin, Vadstena, Sweden). The induction of
AA-amyloidosis has been described in detail earlier [8]. Shortly, at
day 0, under anesthesia groups of 7–8 animals were given 0.1 mg
synthetic fibrils in 0.1 ml in 10% DMSO intravenously, followed
by 0.3 ml 1% silver nitrate subcutaneously in the back. Since
addition of peptide monomers on seeded fibrils takes place at short
ends, fibril suspensions were treated with a burst of ultrasound
prior to injection in order to create fibril fragments. For all animal
Table 1. Synthetic peptides used in the study of amyloid-fibril like properties.
Peptide No. Amino acid sequence Structure Amyloid- like fibrils in vitro
Congo red* Thioflavin S** EM***
1. Ac-DDDDAARRRR-amide a-helix - - Amorphous
2. Ac-GGGGDD surfactant - - Amorphous
3. Ac-VVVVVVDDDD surfactant - - Sheets, no fibrils
4. Ac-AAAAAADDDAAAAAA-amide surfactant - - Small rodlike structures
5. Ac-AAAAAAKK-amide surfactant + + Thin, long, curvy fibrils
6. DAAAAAAR a-helix ++ + Thin, long fibrils
7. EEEEAAAAAAKKKK a-helix (+) (+) Thin, curvy fibrils
8. Ac-VVVVVVD surfactant - - Paper-like sheets
9. Ac-VVVVVVDD surfactant - - Paper-like sheets
10. Ac-AAAAAAD surfactant - - Thin uneven fibrils
11. Ac-FKFEFKFE-amide b-sheet ++ ++ Long, parallel fibrils
12. Ac-RADARADARADARADA-amide b-sheet ++ ++ Heterogeneous bundles of thin fibrils
*The affinity for Congo red and green birefringence in polarized light was semiquantitatively estimated. -, no reaction; (+) partial weak reaction; + weak affinity and
green birefringence. ++ strong affinity and bright green birefringence.
**The strength of fluorescence after labeling with thioflavin S was semiquantitatively estimated. (+) partial weak reaction; + weak fluorescence; ++ strong bright
fluorescence.
***Electron microscopy after that the peptides had been dissolved in dimethyl sulfoxide, diluted in water and incubated for 1 month.
doi:10.1371/journal.pone.0006041.t001
Amyloidogenic Fibrils
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groups, the injections of silver nitrate were repeated on day 7 and
14 and the animals were sacrificed on day 16.
In a second set of experiments, a prolonged amyloid induction
protocol was used. Peptides, now including some of them not
forming amyloid-like fibrils, were dissolved in DMSO and diluted
with water as described above. After 1 month of incubation in
room temperature, 0.1 mg of the material was given intravenously
and 0.3 ml 1% silver nitrate subcutaneously in the back to groups
of 7 mice. Further injections of 0.1 ml 1% silver nitrate were given
subcutaneously after 1, 2 and 3 weeks and the animals were
sacrificed on day 23.
Since the properties of fibrils might change after long-term
maturing, a third series of mice were tested will all peptides after
they had incubated as above for 1 year. The prolonged protocol
(23 days) was applied.
In a separate experiment peptide No. 12 was dissolved directly
in distilled water at 1% concentration, instantly forming a fibrillar
network [21,25]. After a short tip-sonication, 0.1 mg was injected
intravenously in 12 mice and silver nitrate was given according to
the prolonged amyloid induction protocol.
For both protocols (16 and 23 days) groups of control mice
received inflammatory challenges identical to the experimental
groups but got only vehicle intravenously. In all the experiments
one half of the removed spleen was squashed between two
microscopical slides, air-dried and examined in a polarization
microscope for the presence of amyloid after that specimens had
been stained with alkaline Congo red [23]. This method allows
examination of more of the organ than after paraffin-embedding
and sectioning. For the animals, given one-year-old material, the
amount of amyloid was semiquantitatively estimated according to
the following scale: 0, no amyloid found; 1+, one or two amyloid-
containing fragments/slide; 2+, more than two amyloid frag-
ments/slide but no coalescent areas; 3+, amyloid-containing
fragments with coalescence; 4+, extensive amyloidosis. Examples
of the four different amyloid grades are given in Fig. 1.
The animal studies were approved by the Local Animal Ethic
Committee at Linko¨ping University, Linko¨ping District Court, PO
Box 365, SE-58103, Linko¨ping, Sweden.
Results
Aggregation properties of peptides
All peptides were easily soluble in DMSO. After dilution with
water to 10% DMSO, gel particles were seen within minutes with
peptide No. 11. These where strongly congophilic and showed
bright green birefringence in polarized light. The other solutions
stayed clear. The diluted preparations were incubated for up to 12
months, aliquots were taken for study of amyloid-like materials at
several time-points and occurrence of amyloid-like material was
checked by Congo red staining of dried droplets. Congophilia and
birefringence, a hallmark of amyloid and typical of cross-beta
fibrils had appeared after 1 week for peptides No. 5, 6, 7, 11 and
12, (Table 1) but with somewhat different appearances. The
solution with peptide No. 7 had a precipitate that had affinity for
Congo red stain but exhibited only weak green birefringence.
Peptides No. 6, 11 and 12 all showed typical amyloid appearance
after staining with Congo red with a strong green birefringence at
polarization microscopy. No congophilic materials developed in
the other solutions ever after incubation for 12 months.
Fluorescence after labeling with thioflavin S strikingly paralleled
the findings with Congo red (Table 1 and Fig. 2). Thus, thioflavin
S fluorescence was only seen with material from peptides 5, 6, 7,
Figure 1. Semiquantitative estimation of amyloid deposits in splenic squash preparations. A, grade 1. Only one or two amyloid particles
are found in the slide. B, grade 2. Several small amyloid deposits are found. C, grade 3. More widely spread amyloid deposits often with large particles
appear. D, grade 4. Extensive amyloid material all over the slide. Amyloid deposits are marked by arrows. Bar = 50 mm.
doi:10.1371/journal.pone.0006041.g001
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11 and 12. Particularly strong labeling was seen with peptides 11
and 12 (Fig. 2).
Using electron microscopic examination, (Fig. 3) notable
differences were seen between the different peptide preparations
but a variation was also apparent with the same peptides. Peptide
No. 5 (AAAAAAKK) gave rise to thin (3–4 nm), relatively
long fibrils, often aligned laterally to tape-like structures up to
20 nm in width. Some short fibrils also appeared. In contrast
peptide No. 6 (DAAAAAAR) showed about 8 nm thick, slender
fibrils of varying length with little tendency to aggregate laterally.
Peptide No. 7 (EEEEAAAAAAKKKK) consisted of curvy, rope-
like structures in which about 5 nm thick fibrils were aligned
parallel but also small, straight fibrils occurred. Fibrils from
peptide No. 11 (FKFEFKFE) were very long, slender and even
with a diameter of about 10 nm. They were possibly composed of
two very closely aligned parallel filaments. No short fibril
fragments were seen. Material from peptide No. 12 (RADAR-
ADARADARADA) exhibited a highly heterogeneous morpholo-
gy. The basic structure seemed to be thin filaments of less than
3 nm width, arranged in irregular bundles of varying length.
Peptides No. 3, 8 and 9 showed thin, flat, somewhat paper-like
arrangements.
Effects of fibrils on induction of amyloidosis in mice
In the first series (16 days), the ability of amyloid-like fibrils 5, 6,
7, 11 and 12 to enhance the development of murine AA-
amyloidosis was tested. Administration of the different peptide
fibrils intravenously had no apparent direct effects in the mice. At
the end of the experiment, squash preparations of spleen (Fig. 1),
which is the initial site for AA-amyloid deposition (Fig. 4), were
scrutinized for the presence of amyloid by an investigator not
knowing the origin of the material. Amyloid was found in the
spleen of three animals, two of which had received peptide No. 11
and one with peptide No. 12 (Table 2). One of the mice in group
12 died during the experiment.
Given the low number of amyloidotic mice with the 16 day
protocol the rest of the experiments were prolonged to 23
days. Amyloid developed in 1 and 2 animals given peptide
No. 5 and 6, respectively. Of the 7 mice given peptide No. 12, 4
animals developed splenic amyloid deposits (Table 2). This
experiment also included peptides 1 and 2. None of the animals
administered with these peptides showed any evidence of amyloid
deposition.
All of the peptide materials were matured for 1 year and then
tested for their ability to accelerate induction of AA-amyloidosis.
As seen in Table 2, particularly peptide No. 12 was effective in this
respect. Interestingly, when effect of fibrils with amyloid properties
(fluorescence with thioflavin S and affinity for Congo red and
subsequent green birefringence; peptides 5, 6, 7, 11 and 12) was
compared with that of aggregates without these properties
(peptides 1, 2, 3, 4, 8, 9 and 10), it was evident that the
amyloid-like fibrils were significantly more amyloid-accelerating
than the others (p,0.001, Fisher’s exact test). However,
quantitative estimation of the amount of deposits in amyloid-
positive animals did not reveal any apparent difference between
the peptides (Table 2).
In the control group of animals only receiving vehicle
intravenously in addition to the inflammatory stimulus, no
amyloid was detected in any animal. The group of animals that
received peptide No. 12 as a preformed hydrogel combined with
silver nitrate subcutaneously was also free of amyloid.
Discussion
Amyloidosis is a group of devastating disorders in which
proteins or peptides undergo conformational changes and
undertake an abnormal b-sheet structure, leading to assemblies
into highly ordered thin filaments which, in turn, arrange
parallel, often with a twist, to the final protease-resistant fibrils.
The seeding mechanism acts by addition of new monomers to the
short ends of the preformed fibrils. Whether this occurs with
monomers that already have adopted an amyloid-prone confor-
mation or the preformed fibrils induce such structure in molecules
is not known.
Seeding in vitro is protein-specific and already small differences
in amino acid sequence can reduce the efficacy significantly
[16,17]. However, cross-seeding may occur in vitro and it has been
shown that Ab fibrils efficiently seed human IAPP [17]. The
dramatic reduction in time for the development of experimental
Figure 2. Small drops of aggregated synthetic peptides were dried on microscopical slides, labeled with thioflavin S and examined
in a fluorescence microscope. The figure shows that peptides No. 5, 6, 7, 11 and 12 exhibited affinity for the dye and fluorescence. Peptide
No. 10, although fibrillar by electron microscopy, did not show this amyloid-like property. Bar = 24 mm.
doi:10.1371/journal.pone.0006041.g002
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AA-amyloidosis in vivo by amyloid fibrils either given intravenously
or orally is also believed to occur by a seeding mechanism. The
cross-seeding phenomenon, shown in vitro, obviously also can take
place in vivo. Thus, the time for the development of AA-
amyloidosis can be greatly shortened not only by extracted fibrils
from another animal (i.e. AEF) but also to a certain degree by
amyloid fibrils of other biochemical composition [26], (Wester-
mark et al., unpublished), by synthetic fibrils from segments of
known amyloid fibril proteins [18,19] and by naturally occurring,
amyloid-like fibrils such as Bombyx mori silk, Sup35 or curli from E.
coli [20,27]. Similar findings have been obtained with the
apolipoprotein A-2 murine model of systemic amyloidosis
[9,28,29].
Some of the peptides (peptides No. 6 and 7), designed to adopt
a-helix conformation, assembled into amyloid-like fibrils with
affinity of Congo red and green birefringence, typical of repeated
b-sheet structure. However, motives in several of the known
amyloid fibril proteins, including the prion protein [30,31] and
protein AA [32], transform from a native a-helical state into b-
sheet conformation in amyloidogenesis.
The present study shows that some fibrils, made from
synthetically designed peptides, with amyloid-properties including
affinity for Congo red with concomitant green birefringence in
polarized light, also may enhance AA-amyloidosis in the murine
experimental model. Thus, 4 out of 5 amyloid-like peptide-fibrils
had some effect in vivo. The apparent efficacy varied and the most
Figure 3. All aggregated peptides, listed in Table 1 were examined in transmission electron microscopy. Peptides No. 4, 5, 6, 7, 10, 11
and 12 formed fibrillar assemblies while peptides No. 3, 8 and 9 gave rise to paper-like sheets. Bar = 200 nm.
doi:10.1371/journal.pone.0006041.g003
Amyloidogenic Fibrils
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amyloidogenic peptide seemed to be RADARADARADARADA
when fibrils were made by dilution of the peptide initially dissolved
in DMSO. Interestingly, when the same peptide formed fibrils
after being dissolved directly in water, no amyloidogenic properties
were noted in the used system. Such fibrils did not bind Congo red
and showed no green birefringence in polarized light. Obviously
the same peptide can obtain fibrillar structures with different
properties. It has been found that the morphology and properties
of seeded fibrils depend on the seed and that different metastable
morphologies can be obtained with one and the same peptide
[33,34]. The seeding mechanism it is not understood but it is
possible that subtle variations in secondary and tertiary structure
of an amyloid fibril protein can alter the efficacy of cross-seeding
and that a perfect fit at critical regions is necessary for a monomer
to dock. Given the finding that not every mouse developed
amyloidosis with any of the synthetic fibrils, such exact fit in cross-
seeding may be rare and perhaps transient.
These experiments were carried out in a mouse model of
systemic AA-amyloidosis and nothing is known regarding the
possible initiation by environmental factors of the human
counterpart. However, it is by no way ruled out that human
amyloid diseases also can be initiated by a seeding mechanism,
either by natural homologous fibrils or by fibrils from animals
[35]. In addition, as is shown in this work, it is necessary to be
aware of the possibility that also designed synthetic peptide fibrils
may introduce new risk factors. One such risk is that fibrils may
Table 2. Effects of peptides on the development of AA-amyloidosis in mice.
Peptide No. Amino acid sequence Duration of inflammation Grade£
16 days$ 23 days$ 23 days*
1. Ac-DDDDAARRRR-amide N/A 0/7# 0/6# 0
2. Ac-GGGGDD N/A 0/7 0/5 0
3. Ac-VVVVVVDDDD N/A N/A 0/6 0
4. Ac-AAAAAADDDAAAAAA-amide N/A N/A 0/8 0
5. Ac-AAAAAAKK-amide 0/7 1/7 2/7 1,2
6. DAAAAAAR 0/7 2/6 1/5 1
7. EEEEAAAAAAKKKK 0/7 0/7 0/7 0
8. Ac-VVVVVVD N/A N/A 1/8 1
9. Ac-VVVVVVDD N/A N/A 0/6 0
10. Ac-AAAAAAD N/A N/A 0/8 0
11. Ac-FKFEFKFE-amide 2/7 0/7 3/7 1,1,2
12. Ac-RADARADARADARADA-amide 1/6 4/7 5/6 1,1,1,1,4
13. Ac-RADARADARADARADA-amide N/A 0/12 N/A N/A
$diluted peptide solutions matured for 1 month.
*diluted peptide solutions matured for 1 year.
£amyloid grade semiquantitatively estimated according to 0, no amyloid found; 1+, one or two amyloid-containing fragments/slide; 2+, more than two amyloid
fragments/slide but no coalescent areas; 3+, amyloid-containing fragments with coalescence; 4+, extensive amyloidosis. The amyloid grade of each positive mouse is
given.
#Number of mice with amyloidosis/total number of animals. Several animals had to be taken out from the experiment due to development of skin ulcers at the site of
silver nitrate injection. None of these animals had developed amyloid deposits.
N/A, not applicable.
Peptides 1–12 were dissolved in dimethyl sulfoxide and then diluted in water. Peptide 13 was directly dissolved in water.
doi:10.1371/journal.pone.0006041.t002
Figure 4. Amyloid deposits perifollicularly in the spleen. Typically, this is the first region where systemic AA amyloid is seen in the mouse.
Bar = 50 mm.
doi:10.1371/journal.pone.0006041.g004
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start protein misfolding and aggregation, leading to amyloid
diseases.
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